Survival rate

Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001

Retrieved on: 
Friday, November 10, 2023
Priority review, Korean Ministry of Culture, Safety, MFDS, Cancer, GBM, Clinical trial, Mortality, Fast track (FDA), Patient, Reverse transcriptase, Central nervous system, FDA, Survival rate, Sympathetic nervous system, Messenger, Therapy, Accelerated approval (FDA), RNA, Pharmaceutical industry, Medical device, Food, Glioblastoma

Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs, thus enabling drugs to reach patients sooner.

Key Points: 
  • Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs, thus enabling drugs to reach patients sooner.
  • If relevant criteria are met, the drug with Fast Track Designation may also be eligible for Accelerated Approval and Priority Review.
  • GBM is known as the most malignant tumor in Central Nervous system with high mortality rate but lacks effective therapies.
  • "We are proud to receive Fast Track Designation from the FDA," said Dr. Seong-Wook Lee, Chief Executive Officer of Rznomics.

November is Pancreatic Cancer Awareness Month

Retrieved on: 
Wednesday, November 8, 2023
FDA, Holiday, IND, John Engen, Legislation, Pancreatic tumor, EDV, ANDC, Disease, Cancer, Neoplasm, Rivian EDV, Survival rate, Pancreatic cancer, Safety, Oncology, PDAC, Drug resistance, Patient, Drug discovery, Investigational New Drug, Pharmaceutical industry, L.A

EnGeneIC, an Australian/USA biotechnology company, has developed a proprietary targeted nanocell-based therapeutic focused on treatment of low survival solid-tumors, including PDAC.

Key Points: 
  • EnGeneIC, an Australian/USA biotechnology company, has developed a proprietary targeted nanocell-based therapeutic focused on treatment of low survival solid-tumors, including PDAC.
  • The nanocell (designated EDVTM; EnGeneIC Dream Vector) is best described as an Antibody-Nanocell-Drug-Conjugate (ANDC) which also stimulates a powerful anti-tumour immune response.
  • Amazingly, after 15 months of EDV therapy, the patient’s cancer has disappeared and this has been achieved with minimal side effects.
  • In fact, the patient’s quality of life improved so much that she was allowed EDV-treatment breaks for holidays in Paris and Hawaii.

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Tuesday, November 7, 2023
Neoplasm, Survival, CAR, Combination, Glioma, Therapy, ASO, Regeneron Pharmaceuticals, Head, PD-1, The Co Founder, Merck, CNS, Microglia, Kidney, Bladder cancer, TLR9, OTCQB, CD8, Mouse, Environment, City, Immunotherapy, B cell, Disease, Survival rate, Brain, Society, GL261, Patient, Immunosuppression, Therapure BioPharma Inc, Pharmaceutical industry, Pembrolizumab, Cancer, Duet

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma.

Key Points: 
  • DUET-102 is a double-stranded antisense oligonucleotide (“ASO”) STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma.
  • Glioma is a common type of tumor originating in the glial cells of the brain.
  • DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma.
  • There is an acute need for new treatment options for glioma, which have seen no significant advances in the past decade.

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

Retrieved on: 
Tuesday, November 7, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, MB, Neoplasm, Metastasis, OTC Markets Group, Cancer, MD, US Foods, Liver, Doctor of Philosophy, Phenotype, Kidney, Trypsinogen, Malignancy, Extracellular matrix, Tissue, Lung, Growth, Chymotrypsinogen, Survival rate, Skin, Pancreatic cancer, University, Gene, Master of Science, Brain, Tumor microenvironment, Bachelor of Medicine, Bachelor of Surgery, PDAC, Apoptosis, Patient, Breast, Gene expression, PRP, Prostate, PPCB, Medical imaging, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).
  • Various methods, including apoptosis (programmed cell death) and viability analysis, live/dead assays, and RT-qPCR (real time quantification of gene expression) analyses confirmed PRP enhances the sensitivity of pancreatic tumor cells to standard chemotherapy treatment and decreases expression of genes related to chemoresistance.
  • A synergistic ratio of 1:6 inhibits growth of most tumor cells.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

Malaysia Healthcare Promotes Regular Screenings for Breast Cancer Prevention

Retrieved on: 
Tuesday, October 31, 2023
Nipple discharge, 3D, Breast self-examination, Survival, Research, National Center for Functional Glycomics, MRI, Ageing, Breast, Molecular Modeling Database, Flaky pastry, UMSC, Breast pain, BRCA1, Mortality, Skin, Economist, Breast-conserving surgery, BRCA2, Economist Intelligence Unit, Recurrence, Breast cancer, Survival rate, Stage 4, Blood, Swelling, Red, National Center for Biotechnology Information, Bandar Sunway, Agent handling, Woman, Cancer, Pain, Patient, Diagnosis, Associate, Medical imaging, Hospital

KUALA LUMPUR, Malaysia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Malaysia Healthcare encourages global citizens to practice regular examination and screenings as a crucial step in preventing breast cancer.

Key Points: 
  • KUALA LUMPUR, Malaysia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Malaysia Healthcare encourages global citizens to practice regular examination and screenings as a crucial step in preventing breast cancer.
  • With healthcare facilities that are equipped with innovative screening procedures, Malaysia Healthcare is committed to making breast cancer early detection accessible for global citizens.
  • In conjunction with the breast cancer awareness month, Malaysia Healthcare shed light on the significance of early diagnosis as well as the cutting-edge screening procedures provided by several of its healthcare facilities.
  • “We strongly advocate regular self-examination and frequent breast screening especially for women aged 40 and above to detect breast cancer at an early stage.

ClearNote Health Joins the Pancreatic Cancer Early Detection (PRECEDE) Consortium in New Partnership to Reduce Cancer Mortality

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Health, Oncology, Other Health, Nucleic acid thermodynamics, Pancreatic cyst, Pancreas, Associate professor, Type 2 diabetes, McGill University, Disease, Risk, Cancer, Machine learning, Survival rate, Annual general meeting, Pancreatic cancer, Algorithm, Patient, DNA, Pharmaceutical industry, Medical imaging

ClearNote® Health, a cancer detection company focused on identifying cancer earlier in people at high risk for the deadliest cancers to enable longer lives, today announced it has signed an agreement to partner with the Pancreatic Cancer Early Detection (PRECEDE) Consortium .

Key Points: 
  • ClearNote® Health, a cancer detection company focused on identifying cancer earlier in people at high risk for the deadliest cancers to enable longer lives, today announced it has signed an agreement to partner with the Pancreatic Cancer Early Detection (PRECEDE) Consortium .
  • The PRECEDE Consortium is an international, multi-institutional collaborative group of experts working to improve early detection for those with a heritable risk for pancreatic cancer, or those with pancreatic cysts, through a novel model of collaboration and data sharing.
  • “ClearNote Health and PRECEDE share a common mission – to increase the survival rate for pancreatic cancer.
  • ClearNote Health will join and present at the PRECEDE Consortium’s Annual Meeting in New York City on December 6-7, 2023.

STAND UP TO CANCER AND JEAN TREBEK LAUNCH THE ALEX TREBEK FUND, PAYING HOMAGE TO LATE 'JEOPARDY!' HOST, LAUNCH $1 MILLION INITIAL PLEDGE FOR PANCREATIC CANCER RESEARCH

Retrieved on: 
Wednesday, November 1, 2023
Knowledge, Grief, Pancreatic cancer, Research, Survival, SU2C, Survivor, Mortality, Cancer, Estate, Disease, Most, Survival rate, LOS, Patient, Diagnosis, Pharmaceutical industry, Jeopardy!

LOS ANGELES, Nov. 1, 2023 /PRNewswire/ -- Stand Up To Cancer® (SU2C) and Jean Trebek today announced the launch of The Alex Trebek Fund to accelerate critical research with the goal of better treating pancreatic cancer, which has the highest mortality rate of all major cancers. With over $1 million in contributions already raised through a generous donation from Jean Trebek, wife of the late Alex Trebek, and the Estate of Barbara Hanania, SU2C will continue to fundraise throughout the month of November, Pancreatic Cancer Awareness Month, and beyond in support of patients and families impacted by this deadly disease. 

Key Points: 
  • The Alex Trebek Fund will honor and commemorate the legacy of the beloved and iconic late host of Jeopardy!.
  • Alex Trebek was diagnosed with stage four pancreatic cancer in 2019 and tragically lost his battle with the disease the following year.
  • While pancreatic cancer diagnosis is increasing, in 2023, pancreatic cancer survival went up.
  • To learn more about The Alex Trebek Fund and to make a donation, please visit StandUpToCancer.org/TheAlexTrebekFund .

American Heart Association Supports Sudden Cardiac Arrest Foundation's Cardiac Arrest Survivor Alliance™

Retrieved on: 
Tuesday, October 31, 2023
American Heart Association, Survival, Stroke, Cardiac arrest, CASA, SCA, Survivor, Cardiopulmonary resuscitation, Arrest, Heart, Estate (law), CPR, Survival rate, Medical device

PITTSBURGH, Oct. 31, 2023 /PRNewswire-PRWeb/ -- The American Heart Association is a supporter of the Cardiac Arrest Survivor Alliance™ (CASA) program of the Sudden Cardiac Arrest Foundation. CASA is an online resource for people who have been impacted by sudden cardiac arrest (SCA) or the abrupt loss of heart function. The online community aims to help survivors and loved ones, as well as rescuers and advocates.

Key Points: 
  • The American Heart Association is a supporter of the Cardiac Arrest Survivor Alliance™ (CASA) program of the Sudden Cardiac Arrest Foundation .
  • PITTSBURGH, Oct. 31, 2023 /PRNewswire-PRWeb/ -- The American Heart Association is a supporter of the Cardiac Arrest Survivor Alliance™ (CASA) program of the Sudden Cardiac Arrest Foundation .
  • "We are honored that the American Heart Association supports the Cardiac Arrest Survivor Alliance™," said Mary Newman, Sudden Cardiac Arrest Foundation president.
  • "The American Heart Association has a goal to double survival from cardiac arrest by 2030," said Tammy Gregory, executive vice president of the American Heart Association.

Kernal Biologics to Present at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
Therapy, Business development, MD, Novel, Doctor of Philosophy, Poster, Quality of life, SITC, Immunotherapy, Systemic, Survival rate, Messenger, Tumor microenvironment, Society, Cancer, Patient, Pharmaceutical industry, Vaccine, LNP

CAMBRIDGE, Mass., Oct. 31, 2023 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced it is presenting a poster at the Society for Immunotherapy of Cancer 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA.

Key Points: 
  • KR-336 Data Support Use of Onco-selective mRNA LNPs as a Novel, Promising Modality for Systemic Immuno-oncology Applications
    CAMBRIDGE, Mass., Oct. 31, 2023 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced it is presenting a poster at the Society for Immunotherapy of Cancer 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA.
  • The poster presentation features preclinical insights into KR-336, an onco-selective mRNA LNP therapeutic that Kernal Bio has rationally designed using their mRNA2.0 platform to be selectively translated into therapeutic protein within the tumor microenvironment.
  • "At SITC, we look forward to reporting the outcome of in vivo proof-of-concept studies for systemic mRNA LNP administration, which resulted in robust anti-tumor effectiveness."
  • Details for the Kernal Bio presentation are as follows:
    Poster Presentation: Systemically Administered Onco-Selective mRNA LNP Achieves Tumor Regression and Improves Overall Survival, As Monotherapy
    Presenter: Matthew Strout, MD, PhD, Vice President of Business Development, Kernal Biologics

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

Retrieved on: 
Tuesday, October 24, 2023
Glomus tumor, SOC, Head, Cholangiocarcinoma, Survival rate, University, Therapy, MD Anderson Cancer Center, Patient, Pharmaceutical industry

The Company had previously announced the first patient in the head and neck squamous cell carcinoma cohort of the study had been treated.

Key Points: 
  • The Company had previously announced the first patient in the head and neck squamous cell carcinoma cohort of the study had been treated.
  • The BOLSTER trial is a basket trial being conducted at approximately 40 sites in North America, Europe, and Asia-Pacific.
  • Total trial enrollment of 120 patients is expected to be completed in the second half of 2024.
  • “We are excited to announce treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER trial.